Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
11.80
+0.18 (1.55%)
Mar 6, 2026, 10:50 AM EST - Market open
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $424.80 million as of March 6, 2026. Its market cap has decreased by -7.71% in one year.
Market Cap
424.80M
Enterprise Value
173.55M
1-Year Change
-7.71%
Ranking
Category
Stock Price
$11.80
Market Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has increased from $251.01M to $424.80M, an increase of 69.23%. That is a compound annual growth rate of 12.85%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 5, 2026 | 418.32M | 13.47% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Altimmune | 438.94M |
| Assembly Biosciences | 437.50M |
| Solid Biosciences | 437.08M |
| NovaBridge Biosciences | 419.66M |
| Upstream Bio | 414.48M |
| Atea Pharmaceuticals | 414.07M |
| Niagen Bioscience | 409.26M |
| DiaMedica Therapeutics | 406.66M |